Header Logo

Connection

Nomathemba Chandiwana to Humans

Back to Details
This is a "connection" page, showing publications Nomathemba Chandiwana has written about Humans.
Nomathemba Chandiwana
Connection Strength
0,824
Humans
  1. Novel anti-obesity drugs for people with HIV. Lancet HIV. 2024 Aug; 11(8):e502-e503.
    View in: PubMed
    Score: 0,071
  2. Obesity is South Africa's new HIV epidemic. S Afr Med J. 2024 Mar 18; 114(3):e1927.
    View in: PubMed
    Score: 0,069
  3. Weight Gain After HIV Therapy Initiation: Pathophysiology and Implications. J Clin Endocrinol Metab. 2024 Jan 18; 109(2):e478-e487.
    View in: PubMed
    Score: 0,069
  4. Community-based management of a five-arm randomised clinical trial in COVID-19 outpatients in South Africa: challenges and opportunities. Trials. 2023 Oct 04; 24(1):635.
    View in: PubMed
    Score: 0,067
  5. Safety and efficacy of four drug regimens versus standard-of-care for the treatment of symptomatic outpatients with COVID-19: A randomised, open-label, multi-arm, phase 2 clinical trial. EBioMedicine. 2022 Dec; 86:104322.
    View in: PubMed
    Score: 0,063
  6. The predicted risk of adverse pregnancy outcomes as a result of treatment-associated obesity in a hypothetical population receiving tenofovir alafenamide/emtricitabine/dolutegravir, tenofovir disoproxil fumarate/emtricitabine/dolutegravir or tenofovir disoproxil fumarate/emtricitabine/efavirenz. AIDS. 2021 12 15; 35(Suppl 2):S117-S125.
    View in: PubMed
    Score: 0,059
  7. Impact of long-acting therapies on the global HIV epidemic. AIDS. 2021 12 15; 35(Suppl 2):S137-S143.
    View in: PubMed
    Score: 0,059
  8. Unexpected interactions between dolutegravir and folate: randomized trial evidence from South Africa. AIDS. 2021 02 02; 35(2):205-211.
    View in: PubMed
    Score: 0,056
  9. High loss to follow-up of children on antiretroviral treatment in a primary care HIV clinic in Johannesburg, South Africa. Medicine (Baltimore). 2018 Jul; 97(29):e10901.
    View in: PubMed
    Score: 0,047
  10. DORA: 48-week weight and metabolic changes in Black women with HIV, in a phase IIIb switch study from dolutegravir- or efavirenz- to doravirine-based first-line antiretroviral therapy. HIV Med. 2025 Jan; 26(1):81-96.
    View in: PubMed
    Score: 0,018
  11. Regional variation in weight change after the transition to dolutegravir in Uganda and South Africa. AIDS. 2024 07 15; 38(9):1314-1322.
    View in: PubMed
    Score: 0,017
  12. Determinants of early change in serum creatinine after initiation of dolutegravir-based antiretroviral therapy in South Africa. Br J Clin Pharmacol. 2024 May; 90(5):1247-1257.
    View in: PubMed
    Score: 0,017
  13. Perceptions of Health, Body Size, and Nutritional Risk Factors for Obesity in People with HIV in South Africa. AIDS Behav. 2024 Jan; 28(1):367-375.
    View in: PubMed
    Score: 0,017
  14. Pharmacogenetics of tenofovir renal toxicity in HIV-positive Southern Africans. Pharmacogenet Genomics. 2023 07 01; 33(5):91-100.
    View in: PubMed
    Score: 0,016
  15. Weight and Metabolic Changes After Switching From Tenofovir Alafenamide/Emtricitabine (FTC)+Dolutegravir (DTG), Tenofovir Disoproxil Fumarate (TDF)/FTC + DTG, and TDF/FTC/Efavirenz to TDF/Lamivudine/DTG. Clin Infect Dis. 2023 04 17; 76(8):1492-1495.
    View in: PubMed
    Score: 0,016
  16. Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population. CPT Pharmacometrics Syst Pharmacol. 2023 06; 12(6):821-830.
    View in: PubMed
    Score: 0,016
  17. Pharmacogenetics of tenofovir clearance among Southern Africans living with HIV. Pharmacogenet Genomics. 2023 06 01; 33(4):79-87.
    View in: PubMed
    Score: 0,016
  18. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries. AIDS. 2023 05 01; 37(6):1009-1011.
    View in: PubMed
    Score: 0,016
  19. Drug resistance and use of long-acting ART. Lancet HIV. 2022 Jun; 9(6):e374-e375.
    View in: PubMed
    Score: 0,015
  20. Weight gain stopping/switch rules for antiretroviral clinical trials. AIDS. 2021 12 15; 35(Suppl 2):S183-S188.
    View in: PubMed
    Score: 0,015
  21. Stillbirth rate by maternal HIV serostatus and antiretroviral use in pregnancy in South Africa: An audit. S Afr Med J. 2021 09 02; 111(9):822-823.
    View in: PubMed
    Score: 0,015
  22. AGILE: a seamless phase I/IIa platform for the rapid evaluation of candidates for COVID-19 treatment: an update to the structured summary of a study protocol for a randomised platform trial letter. Trials. 2021 Jul 26; 22(1):487.
    View in: PubMed
    Score: 0,014
  23. Genetic Associations with Weight Gain among South Africans who Initiated Dolutegravir-Containing and Tenofovir-Containing Regimens. J Acquir Immune Defic Syndr. 2021 07 01; 87(3):1002-1009.
    View in: PubMed
    Score: 0,014
  24. Experiences of doctoral students enrolled in a research fellowship program to support doctoral training in Africa (2014 to 2018): The Consortium for Advanced Research Training in Africa odyssey. PLoS One. 2021; 16(6):e0252863.
    View in: PubMed
    Score: 0,014
  25. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. Lancet HIV. 2020 10; 7(10):e666-e676.
    View in: PubMed
    Score: 0,014
  26. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med. 2019 08 29; 381(9):803-815.
    View in: PubMed
    Score: 0,013
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.